Skip to main content
Log in

Darunavir

A Review of its Use in the Management of HIV Infection in Adults

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Abstract

Darunavir is an oral nonpeptidic HIV-1 protease inhibitor (PI) that is used, together with a low boosting dose of ritonavir, as part of an antiretroviral therapy (ART) regimen in treatment-experienced and -naive patients with HIV-1 infection.

Compared with early-generation PIs, boosted darunavir has a high genetic barrier to resistance and is active against multidrug-resistant HIV isolates. In clinical trials in treatment-experienced patients with HIV-1 infection receiving an optimized background regimen (OBR), twice-daily boosted darunavir was more effective than investigator-selected ritonavir-boosted control PIs (CPIs) or ritonavir-boosted lopinavir. In clinical trials in treatment-naive patients with HIV-1 infection receiving a fixed background regimen, once-daily boosted darunavir was noninferior to boosted lopinavir at 48 weeks and more effective than boosted lopinavir at 96weeks. Boosted darunavir was generally well tolerated in patientswith HIV-1 infection in clinical trials. It was associated with a lower incidence of diarrhoea than CPIs or lopinavir in treatment-experienced or -naive patients, and fewer lipid abnormalities than lopinavir in treatment-naive patients. Thus, for the management of treatment-experienced or -naive patients with HIV-1 infection, a ritonavir-boosted darunavir-based ART regimen is a valuable treatment option.

Pharmacological Properties

Darunavir is an oral nonpeptidic HIV-1 PI that selectively inhibits the cleavage of HIV gag and gag-pol polyproteins, thereby preventing viral maturation. Darunavir is highly potent against laboratory strains and clinical isolates of wild-type and multidrug-resistant HIV and has limited cytotoxicity. In an in vitro study in MT-2 cells, the potency of darunavir was greater than that of saquinavir, amprenavir, nelfinavir, indinavir, lopinavir and ritonavir. Darunavir binds with high affinity to HIV-1 protease, including multidrug-resistant proteases, and retains potency against multidrug-resistant HIV-1 strains. Although some potential may exist for cross-resistance with amprenavir, darunavir did not display cross-resistance with other PIs in vitro.

In a 24-week analysis of pooled data from the POWER 1 and 2 studies in treatment-experienced patients, 11 protease mutations associated with a reduced response to boosted darunavir were identified (V1 1I, V32I, L33F, I47V, I50V, I54L/M, G73S, L76V, I84V and L89V). The presence of at least three darunavir resistance-associated mutations (prevalent in ≈7–9% of treatment-experienced patients) together with a high number of protease resistance-associated mutations were required to confer darunavir resistance. In the 48-week analysis of treatment-experienced patients with virological failure in the the TITAN study, fewer in the boosted darunavir group than in the boosted lopinavir group developed additional mutations or lost susceptibility to PIs compared with baseline. In treatment-naive patients, no primary PI-resistance-associated mutations developed in patients with an available genotype at baseline and endpoint during 96 weeks of treatment with boosted darunavir or boosted lopinavir.

Oral darunavir, boosted with low-dose ritonavir, is rapidly absorbed, generally reaching peak plasma concentrations within 2.5–4 hours. The bioavailability of oral darunavir is increased by about 30% when taken with food. Darunavir is primarily metabolized by the hepatic cytochrome P450 (CYP) enzymes, primarily CYP3A. The ‘boosting’ dose of ritonavir acts an an inhibitor of CYP3A, thereby increasing darunavir bioavailability. Drug interactions can result when darunavir is coadministered with other drugs that are inducers or inhibitors of, or act as substrates for, CYP3A. The mean elimination half-life of boosted darunavir is ≈15 hours.

Therapeutic Efficacy

In treatment-experienced patients with HIV-1 infection, the therapeutic efficacy of oral twice-daily darunavir 600 mg, boosted with ritonavir 100mg, versus that of investigator selected boosted CPIs (POWER studies) or versus twice-daily boosted lopinavir (administered as a fixed dose combination of lopinavir/ritonavir 400/100 mg) [TITAN study] has been evaluated in phase IIb and III studies. All patients received concurrent treatment with an OBR. Significantly more patients receiving boosted darunavir achieved a viral load reduction from baseline of ≥1 log10 copies/mL (primary endpoint) than boosted CPI recipients at all timepoints, up to and including the final efficacy analysis at 144 weeks, in the combined analyses of POWER 1 and 2. The efficacy of boosted darunavir was noninferior to that of boosted lopinavir at 48 weeks, and was significantly better than boosted lopinavir at 48 and 96 weeks in the TITAN study, as determined by significantly more patients in the darunavir group than in the lopinavir group achieving a viral load of <400 copies/mL (primary endpoint).

In the ARTEMIS study in treatment-naive patients with HIV-1 infection receiving a fixed background regimen of tenofovir and emtricitabine, once-daily boosted darunavir 800 mg was noninferior to boosted lopinavir 800 mg/day at 48 weeks. At 96 weeks, boosted darunavir was found to be more effective than boosted lopinavir, as determined by significantly more patients in the darunavir group than in the lopinavir group achieving a confirmed plasma viral load of <50 copies/mL (primary endpoint).

Tolerability

Boosted darunavir was generally well tolerated in patients with HIV-1 infection in clinical trials, with most events being mild to moderate in severity. At 48-week analyses, the most common adverse events associated with once- or twice-daily boosted darunavir in treatment-experienced or -naive patients were diarrhoea, nausea, headache, upper respiratory tract infection and nasopharyngitis. The most common boosted darunavir-related grade 2–4 laboratory abnormalities in treatment-experienced patients included increased triglycerides and increased total cholesterol.

Overall, boosted darunavir was associated with less diarrhoea than CPIs or boosted lopinavir in treatment-experienced and -naive patients, and a lower incidence of grade 2–4 elevations in triglycerides and total cholesterol than boosted lopinavir in treatment-naive patients. Treatment discontinuation because of adverse events occurred in 3% of boosted darunavir recipients and 7% of boosted lopinavir recipients during 48 weeks of therapy in treatment-naive patients.

Pharmacoeconomic Considerations

Healthcare costs in the UK and US were estimated to be lower with boosted darunavir than with investigator-selected CPIs in treatment-experienced patients with HIV-1 infection in two 1-year cost analyses conducted from the perspective of a healthcare provider and using predicted costs based on CD4+ cell counts and clinical data from the POWER studies. The higher acquisition cost of boosted darunavir compared with CPIs was more than offset by the better efficacy of darunavir.

In modelled cost-effectiveness analyses, boosted darunavir was predicted to be cost effective compared with other boosted CPIs in heavily pretreated adults from a healthcare payer perspective in Europe and from a societal perspective in the US. In a further model of a subgroup of patients with at least one primary International AIDS Society-USA PI mutation, boosted darunavir was predicted to be cost effective compared with boosted lopinavir from a healthcare payer perspective in Europe. The incremental costs per quality-adjusted life-year gained were within commonly accepted thresholds in all cost-effectiveness analyses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Clumeck N, Pozniak A, Raffi F. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 2008 Feb; 9(2): 65–71

    Article  PubMed  CAS  Google Scholar 

  2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2008 November 3; 1–139 [online]. Available from URL: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [Accessed 2008 Nov 12]

  3. Gazzard BG, BHIVA Treatment Guidelines Writing Group. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Medicine 2008; 9: 563–608

    Article  PubMed  CAS  Google Scholar 

  4. Hammer SM, Eron Jr JR, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA Panel. JAMA 2008 Aug; 300(5): 555–70

    Article  PubMed  CAS  Google Scholar 

  5. Perno CF, Moyle G, Tsoukas C, et al. Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs. J Med Virol 2008; 80(4): 565–76

    Article  PubMed  CAS  Google Scholar 

  6. Youle M. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. J Antimicrob Chemother 2007 Dec; 60(6): 1195–205

    Article  PubMed  CAS  Google Scholar 

  7. Fenton C, Perry CM. Darunavir: in the treatment of HIV-1 infection. Drugs 2007; 67(18): 2791–801

    Article  PubMed  CAS  Google Scholar 

  8. Surleraux DLNG, Tahri A, Verschueren WG, et al. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J Med Chem 2005; 48: 1813–22

    Article  PubMed  CAS  Google Scholar 

  9. US FDA. HIV/AIDS list serve archive 2008 [online]. Available from URL: http://www.fda.gov/oashi/aids/ [Accessed 2008 Nov 10]

  10. Johnson &. Johnson. Once-daily Prezista® (darunavir) for treatment-naive adults with HIV-1 receives approval in the European Union as part of combination therapy Prezista now indicated for adults living with HIV at all phases of treatment [online]. Available from URL: http://www.investor.jnj.com/releaseDetail.cfm?releaseid=363375 [Accessed 2009 Mar 12]

  11. De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005 Jun; 49(6): 2314–21

    Article  PubMed  Google Scholar 

  12. Koh Y, Nakata H, Maeda K, et al. Novel bis-tetrahydrofurany-lurethane-containing nonpeptide protease inhibitor (PI) IUC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother 2003 Oct; 47(10): 3123–9

    Article  PubMed  CAS  Google Scholar 

  13. King NM, Prabu-Jeyabalan M, Nalivaika EA, et al. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol 2004 Nov; 78(21): 12012–21

    Article  PubMed  CAS  Google Scholar 

  14. Koh Y, Matsumi S, Das D, et al. Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. J Biol Chem 2007 Sep; 282(39): 28709–20

    Article  PubMed  CAS  Google Scholar 

  15. Nivesanond K, Peeters A, Lamoen D, et al. Conformational analysis of TMC114, a novel HIV-1 protease inhibitor. J Chem Inf Model 2008 Jan; 48(1): 99–108

    Article  PubMed  CAS  Google Scholar 

  16. Dierynck I, De Wit M, Gustin E, et al. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J Virol 2007 Dec; 81(24): 13845–51

    Article  PubMed  CAS  Google Scholar 

  17. Poveda E, de Mendoza C, Parkin N, et al. Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes. AIDS 2008 Mar 12; 22(5): 611–6

    Article  PubMed  CAS  Google Scholar 

  18. De Meyer S, Vangeneugden T, van Baelen B, et al. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses 2008 Mar; 24(3): 379–88

    Article  PubMed  Google Scholar 

  19. De Meyer S, De Paepe E, Vangeneugden T, et al. Effect of baseline and on-treatment mutations on the antiretroviral activity of darunavir/ritonavir and lopinavir/ritonavir: results of a randomised, controlled, phase III study (TITAN) [abstract no. WEPEB038 plus poster]. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 2007 Jul 22–27; Sydney (NSW)

  20. Pozniak A, Opravil M, Beatty G, et al. Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected fected patients: POWER 1 and 2. AIDS Res Hum Retroviruses 2008; 24(10): 1275–80

    Article  PubMed  CAS  Google Scholar 

  21. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007 Jul 7; 370(9581): 49–58

    Article  PubMed  CAS  Google Scholar 

  22. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008 Jul 31; 22(12): 1389–97

    Article  PubMed  CAS  Google Scholar 

  23. Dierynck I, De Meyer S, Lathouwers E, et al. Characterization of virologic failures in the randomized, controlled, phase III ARTEMIS trial in treatment-naive patients: week-96 analysis [abstract no. 655 plus poster]. 16th Conference on Retroviruses and Opportunistic Infections; 2009 Feb 8–11; Montreal (QC)

  24. Lambert-Niclot S, Flandre P, Canestri A, et al. Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir. Antimicrob Agents Chemother 2008 Feb; 52(2): 491–6

    Article  PubMed  CAS  Google Scholar 

  25. Pellegrin I, Wittkop L, Joubert LM, et al. Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study). Antivir Ther 2008; 13(2): 271–9

    PubMed  CAS  Google Scholar 

  26. Moltó J, Santos JR, Pérez-Álvarez N, et al. Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients. Antimicrob Agents Chemother 2008 Nov; 52(11): 3928–32

    Article  PubMed  Google Scholar 

  27. Poveda E, de Mendoza C, Martin-Carbonero L, et al. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. J Antimicrob Chemother 2007 Oct; 60(4): 885–8

    Article  PubMed  CAS  Google Scholar 

  28. Rinehart AR, Picchio G, de Bethune M-P, et al. Prevalence of darunavir resistance-associated mutations in samples received for routine clinical resistance testing [abstract no.44]. 5th European HIV Drug Resistance Workshop; 2007 Mar 28-30; Cascais

  29. Mitsuya Y, Liu TF, Rhee SY, et al. Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment. J Infect Dis 2007 Oct 15; 196(8): 1177–9

    Article  PubMed  CAS  Google Scholar 

  30. Tibotec Therapeutics. Prezista™ (darunavir) tablets full prescribing information (US) [online]. Available from URL: http://www.prezista.com/docs/us [Accessed 2009 Feb 3]

  31. Sekar V, De Meyer S, Vangeneugden T, et al. Pharmacokinetic/ pharmacodynamic(PK/PD) analyses of TMC 114 in the POWER 1 and POWER 2 trials in treatment-experienced HIV-infected patients [abstract no. J121 plus poster]. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5–9; Denver (CO)

  32. Sekar V, Kestens D, Spinosa-Guzman S, et al. The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers. J Clin Pharmacol 2007 Apr; 47(4): 479–84

    Article  PubMed  CAS  Google Scholar 

  33. Back D, Sekar V, Hoetelmans RM. Darunavir: pharmacokinetics and drug interactions. Antivir Ther 2008; 13(1): 1–13

    PubMed  CAS  Google Scholar 

  34. Rachlis A, Clotet B, Baxter J, et al. Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3. HIV Clin Trials 2007 Jul–2007 31; 8(4): 213–20

    Article  PubMed  Google Scholar 

  35. Sekar V, Vanden Abeele C, van Baelen B, et al. Pharmacokinetic/ pharmacodynamic analyses of once-daily darunavir in the ARTEMIS Study [abstract no. 769 plus poster]. 15th Conference on Retroviruses and Opportunistic Infections; 2008 Feb 3; Boston (MA)

  36. Sekar VJ, De Paepe E, van Baelen B, et al. Effect of extrinsic and intrinsic factors on the pharmacokinetics of darunavir/ ritonavir in HIV-1 patients: results of a randomized, controlled, phase III study (TITAN) [abstract no. PS4/5]. 1 1th European AIDS Conference; 2007 Oct 24–27; Madrid, 15

  37. European Medicines Agency. Prezista 300 mg tablets: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/Humans/EPAR [Accessed 2009 Feb 9]

  38. Hoetelmans RMW, Mariën K, De Pauw M, et al. Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers. Br J Clin Pharmacol 2007 Nov; 64(5): 655–61

    Article  PubMed  CAS  Google Scholar 

  39. Sekar VJ, Lefebvre E, Marien K, et al. Pharmacokinetic interaction between darunavir and saquinavir in HIV-negative volunteers. Ther Drug Monit 2007 Dec; 29(6): 795–801

    Article  PubMed  CAS  Google Scholar 

  40. Sekar VJ, De Pauw M, Marien K, et al. Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers. Antivir Ther 2007; 12(4): 509–14

    PubMed  CAS  Google Scholar 

  41. Sekar VJ, Lefebvre E, Guzman SS, et al. Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women. Antiviral Ther 2008; 13(4): 563–9

    CAS  Google Scholar 

  42. Sekar V, Lefebvre E, De Marez T, et al. Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study. Clin Drug Investig 2008; 28(8): 479–85

    Article  PubMed  CAS  Google Scholar 

  43. Sekar VJ, Spinosa-Guzman S, De Paepe E, et al. Darunavir/ ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers. J Clin Pharmacol 2008 Jan; 48(1): 60–5

    Article  PubMed  CAS  Google Scholar 

  44. Sekar VJ, Lefebvre E, De Pauw M, et al. Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers. Br J Clin Pharmacol 2008 Aug; 66(2): 215–21

    Article  PubMed  CAS  Google Scholar 

  45. Scholler-Gyure M, Kakuda TN, Sekar V, et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther 2007; 12(5): 789–96

    PubMed  CAS  Google Scholar 

  46. Sekar VJ, Lefebvre E, De Marez T, et al. Pharmacokinetics of darunavir (TMC 114) and atazanavir during coadministration in HIV-negative, healthy volunteers. Drugs R D 2007; 8(4): 241–8

    Article  PubMed  CAS  Google Scholar 

  47. Sekar VJ, Lefebvre E, De Paepe E, et al. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers. Antimicrob Agents Chemother 2007 Mar; 51(3): 958–61

    Article  PubMed  CAS  Google Scholar 

  48. Sekar V, Lefebvre E, De Marez T, et al. Pharmacokinetic interaction between the HIV protease inhibitors TMC 114 and indinavir in the presence of low-dose ritonavir [abstract no. PP4.15]. International Symposium on HIV and Emerging Infectious Diseases; 2006 Jun 21–23; Toulon

  49. Sekar VJ, Lefebvre E, Boogaerts G, et al. Pharmacokinetic interaction between the protease inhibitors TMC 114 and lopinavir/ritonavir [abstract no. A-367]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27–30; San Francisco (CA)

  50. Abel S, Ridgway C, Hamlin J, et al. An open, randomized, 2-way crossover study to investigate the effect of darunavir/ritonavir on the pharmacokinetics of maraviroc in healthy subjects [abstract no. 55 plus poster]. 8th International Workshop on Clinical Pharmacology of HIV Therapy; 2007 Apr 16-18; Budapest

  51. Hoetelmans RMW, Lasure A, Koester A, et al. The effect of TMC114, a potent next-generation HIV protease inhibitor, with low-dose ritonavir on atorvastatin pharmacokinetics [abstract no. H-865]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30–Nov 2; Washington, DC

  52. Sekar VJ, Spinosa-Guzman S, Marien K, et al. Pharmacokinetic drug-drug interaction between the new HIV protease inhibitor darunavir (TMC114) and the lipid-lowering agent pravastatin [abstract no. 54 plus poster]. 8th International Workshop on Clinical Pharmacology of HIV Therapy; 2007 Apr 16–18; Budapest

  53. Sekar V, Malt EI, De Paepe E, et al. Effect of the HIV protease inhibitor TMC114, coadministered with low-dose ritonavir, on the pharmacokinetics of digoxin in healthy volunteers [abstract no. PII-104]. Clin Pharmacol Ther 2007; 81 Suppl. 1: S83

    Article  Google Scholar 

  54. Sekar V, De Paepe E, De Marez T, et al. Pharmacokinetic interaction between darunavir (TMC114), a new protease inhibitor, and the selective serotonin reuptake inhibitors (SSRIs), paroxetine and sertraline [abstract no. P295 plus poster]. 8th International Congress on Drug Therapy in HIV Infection; 2006 Nov 12–16; Glasgow

  55. Sekar V, Tomaka F, Lavreys L, et al. Pharmacokinetic interaction between darunavir in combination with low-dose ritonavir (DRV/r) and carbamazepine (CBZ) [abstract]. 17th International Aids Conference; 2008 Aug 3–8; Mexico City

  56. Sekar V, Malt EI, De Paepe E, et al. Pharmacokinetic interaction between darunavir (TMC114), a new protease inhibitor, and methadone [abstract no. P294 plus poster]. 8th International Congress on Drug Therapy in HIV Infection; 2006 Nov 12–16; Glasgow

  57. Sekar VJ, Lavreys L, De Paepe E, et al. Pharmacokinetic interaction between darunavir in combination with low-dose ritonavir and rifabutin [abstract no. H-4053]. Joint Annual Meeting of 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Meeting of the Infectious Diseases Society of America; 2008 Oct 25–28; Washingon DC

  58. Mathias A, Shen G, Enejosa J, et al. Lack of pharmacokinetic interaction between ritonavir-boosted GS-9137 (elvitegravir) and darunavir/r [abstract]. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2007 Jul 22–25; Sydney (NSW)

  59. Sekar VJ, Spinosa-Guzman S, De Paepe E, et al. Pharmacokinetic interaction trial between darunavir in combination with low-dose ritonavir and didanosine [abstract]. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2007 Jul 22–25; Sydney (NSW)

  60. Sekar V, De Paepe E, Vangeneugden T, et al. Absence of an interaction between the potent HIV protease inhibitor TMC114 and the fusion inhibitor enfurvirtide in the POWER 3 analysis [abstract no. P54 plus poster]. 7th International Workshop on Clinical Pharmacology of HIV Therapy; 2006 Apr 20–22; Lisbon

  61. Sekar V, Lefebvre E, Marien K, et al. Pharmacokinetic interaction between the antiretroviral agents TMC114 and nevirapine, in the presence of low-dose ritonavir [abstract no. 956]. 44th Annual Meeting of the Infectious Diseases Society of America; 2006 Oct 12–15; Toronto (ON)

  62. Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007 Feb 19; 21(4): 395–402

    Article  PubMed  CAS  Google Scholar 

  63. Haubrich R, Berger D, Chiliade P, et al. Week 24 efficacy and safety of TMC 114/ritonavir in treatment-experienced HIV patients. AIDS 2007 Mar 30; 21(6): F11–18

    Article  PubMed  Google Scholar 

  64. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007 Apr 7; 369(9568): 1169–78

    Article  PubMed  CAS  Google Scholar 

  65. Pozniak A, Jayaweera D, Hoy J, et al. Efficacy of darunavir/ ritonavir in treatment-experienced HIV-1-infected patients at 96 weeks in the POWER 1 and 2 trials [abstract no. P7.2/07]. 1 1th European AIDS Conference; 2007 Oct 24–27; Madrid, 63

  66. Katlama C, Bellos N, Grinsztejn B, et al. POWER 1 and 2: combined final 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg bid in treatment-experienced HIV patients [abstract no. P21]. 9th International Congress on Drug Therapy in HIV Infection; 2008 Nov 9–13; Glasgow

  67. Molina JM, Cohen C, Katlama C, et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr 2007 Sep 1; 46(1): 24–31

    PubMed  CAS  Google Scholar 

  68. Pozniak A, Arastéh K, Molina J-M, et al. POWER 3 analysis: 144-week efficacy and safety results for darunavir/ritonavir 600/100 mg bid in treatment-experienced HIV patients [abstract no. P24 plus poster]. 9th International Congress on Drug Therapy in HIV Infection; 2008 Nov 9–13; Glasgow

  69. Bánhegyi D, Katlama C, Da Cunha C, et al. Phase III TITAN week 96 final analysis: efficacy/safety of darunavir/r (DRV/r) vs. loprinavir/r (LPV/r) in LPV-naïve, treatment-experienced patients [abstract no. P22 plus poster]. 9th International Congress on Drug Therapy in HIV Infection; 2008 Nov 9–13; Glasgow

  70. Mills A, Nelson M, Jayaweera D, et al. ARTEMIS: efficacy and safety of darunavir/ritonavir 800/100 mg once-daily vs lopinavir/ritonavir in treatment-naive, HIV-1-infected patients at 96 wks [abstract no. H-1250c plus poster]. Joint Annual Meeting of 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Meeting of the Infectious Diseases Society of America; 2008 Oct 25–28; Washington, DC

  71. Mascolini M. ARTEMIS study: once-daily darunavir, once-daily lopinavir, and twice daily lopinavir compared [conference report]. 11th European AIDS Conference; 2007 Oct 24–27; Madrid

  72. Boehringer Iingelheim Pharmaceuticals Inc. Aptivus® (tipranavir): prescribing information [online]. Available from URL: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ [Accessed 2009 Mar 12]

  73. Bristol-Myers Squibb. Reyataz® (atazanavir sulphate): prescribing information [online]. Available from URL: http://packageinsertsbms.com/pi/pi_reyataz.pdf [Accessed 2009 Mar 12]

  74. Abbott. Kaletra® (lopinavir/ritonavir). Highlights of prescribing information [online]. Available from URL: http://rxabbott.com/pdf/kaletrapi.pdf [Accessed 2009 Mar 12]

  75. US FDA. Postmarket drug safety information for patients and providers. Darunavir ethalolate (marketed as Prezista) information [online]. Available from URL: http://www.fda.gov/cder/drugSafety [Accessed 2008 Oct 21]

  76. Hill A, Hemmett L, Wilson B. Analysis of costs by CD4 count category for the darunavir/r 600/100 mg bid and control protease inhibitor arms of the POWER 1 and 2 trials. HIV Clin Trials 2007; 8(5): 303–10

    Article  PubMed  Google Scholar 

  77. Hill A, Gebo K. Predicting HIV care costs using CD4 counts from clinical trials. Am J Manag Care 2007 Sep; 13(9): 524–8

    PubMed  Google Scholar 

  78. Moeremans K, Annemans L, Smets E, et al. Cost-effectiveness of darunavir/r in highly treatment-experienced HIV/AIDS patients in different European healthcare settings [abstract no. ES8]. Value Health 2007; 10(6): A239

    Article  Google Scholar 

  79. Mauskopf J, Brogan A, Smets E, et al. Cost-effectiveness of darunavir (TMC114)/ritonavir compared with currently available protease inhibitors in treatment-experienced HIV patients [abstract no. P51 plus poster]. 8th International Congress on Drug Therapy in HIV Infection; 2006 Nov 12–16; Glasgow

  80. Moeremans K, Hemmett LC, Hjelmgren J, et al. Cost-effectiveness of darunavir/ritonavir 600/100mg bid in treatment-experienced, LPV/R-naive, PI-resistant, HIV-infected adults in the United Kingdon, Belgium, Italy and Sweden [abstract no PIN55]. International Society for Pharmacoeconomics and Outcomes Research 1 1th Annual European Congress; 2008 Nov 8–11; Athens

  81. Chen RY, Accortt NA, Westfall AO, et al. Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis 2006; 42: 1003–10

    Article  PubMed  CAS  Google Scholar 

  82. Brogan A, Mauskopf J, Martin S, et al. Cost-effectiveness analysis of darunavir/r for HIV infection in treatment-experienced adults in the US: understanding the uncertainty in the estimates [abstract no. IN1]. Value Health 2007; 10(3): A18

    Article  Google Scholar 

  83. Booth CL, Garcia-Diaz AM, Youle MS, et al. Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J Antimicrob Chemother 2007; 59: 517–24

    Article  PubMed  CAS  Google Scholar 

  84. Bennett D, McCormick L, Kline R, et al. US surveillance of HIV drug resistance at diagnosis using HIV diagnostic sera [abstract no. 674]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22–25; Boston (MA)

  85. Richman DD, Morton SC, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004; 18(10): 1393–401

    Article  PubMed  Google Scholar 

  86. Orman JS, Perry CM. Tipranavir: a review of its use in the management of HIV infection. Drugs 2008; 68(10): 1435–63

    Article  PubMed  CAS  Google Scholar 

  87. Hill A, Moyle G. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs control protease inhibitor in the POWER and RESIST trials. HIV Med 2007 May; 8(4): 259–64

    Article  PubMed  CAS  Google Scholar 

  88. Tibotec Therapeutics. Intelence™ (etravirine) tablets. US prescribing information [online]. Available from URL: http://www.intelence-info.com/intelence/assets/pdf/INTELENCE_PI.pdf [Accessed 2008 Nov 14]

  89. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007 Jul 7; 370(9581): 29–38

    Article  PubMed  CAS  Google Scholar 

  90. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC 125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007 Jul 7; 370(9581): 39–48

    Article  PubMed  CAS  Google Scholar 

  91. Yazpandanah Y, Fagard C, Descamps D, et al. High rate of virologic success with raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: results of the ANRS 139 TRIO trial [abstract]. 17th International AIDS Conference; 2008 Aug 3–8; Mexico City

  92. US National Institutes of Health. Clinical Trials NCT00524368 and NCT00421551 [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Mar 3]

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kate McKeage.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McKeage, K., Perry, C.M. & Keam, S.J. Darunavir. Drugs 69, 477–503 (2009). https://doi.org/10.2165/00003495-200969040-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200969040-00007

Keywords

Navigation